KA/EN
Register
Medicines reference
Search
Search
Active substance

Riboflavin

Favourites

B vitamin. Registered in Georgia: 2 human medicines. Forms: coated tablet, solution.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Riboflavin
Georgian name
რიბოფლავინი
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
2 of 2 forms
Products
Benevron B, Benevron BF
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Benevron B, Solution

solution for injection, 3 ml ampoule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed deep-IM use of the exact Benevron B human ampoule for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron B

solution for injection, 3 ml ampoule, human medicine
Assessed clinical scopeDog · Proposed deep-IM use of the exact Benevron B human ampoule for a diagnosed vitamin deficiency or adjunctive neurologic role · Intramuscular
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-045603, რ-038060 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical canine score cannot be assigned responsibly. AEM DV 22-01101 and Kazakhstan SPC ҚР-ДЗ-5№121984 verify the exact 3 ml human ampoule, four-vitamin composition and deep-IM human route. They provide no dog/cat dose, veterinary PK, target-animal safety margin or clinical outcome evidence. The human schedule and an isolated clinic-chart volume are not transferable, and the ampoule also contains 60 mg benzyl alcohol.

Exact human identity and deep-IM route are verified; a veterinary dose and benefit-risk are not. Do not transfer the human schedule or infer “slow injection.”

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact ampoule. Do not scale the human schedule, copy an isolated clinic-chart volume or derive a mixture dose from one component.
  • The exact official route is deep IM. “Slowly” is not stated in the audited primary documents; do not add it or extrapolate IV, SC or oral use.
  • AEM and the Kazakhstan SPC describe a human medicine; this is not a veterinary authorisation. Exact dog/cat PK, efficacy and repeated-dose safety remain absent.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each 3 ml ampoule contains 250 mg pyridoxine and 60 mg benzyl alcohol with the other vitamins. Dog/cat local tolerance, repeated-dose safety and therapeutic margin are not established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Parenteral thiamine can cause serious hypersensitivity. Use aseptic technique, review excipients and ensure readiness to manage an acute reaction.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron B Azerbaijan register2022
  2. Benevron B Kazakhstan SPC2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed deep-IM use of the exact Benevron B human ampoule for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron B

solution for injection, 3 ml ampoule, human medicine
Assessed clinical scopeCat · Proposed deep-IM use of the exact Benevron B human ampoule for a diagnosed vitamin deficiency or adjunctive neurologic role · Intramuscular
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-045603, რ-038060 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical feline score cannot be assigned responsibly. AEM DV 22-01101 and Kazakhstan SPC ҚР-ДЗ-5№121984 verify the exact 3 ml human ampoule, four-vitamin composition and deep-IM human route. They provide no dog/cat dose, veterinary PK, target-animal safety margin or clinical outcome evidence. The human schedule and an isolated clinic-chart volume are not transferable, and the ampoule also contains 60 mg benzyl alcohol.

Exact human identity and deep-IM route are verified; a veterinary dose and benefit-risk are not. Do not transfer the human schedule or infer “slow injection.”

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact ampoule. Do not scale the human schedule, copy an isolated clinic-chart volume or derive a mixture dose from one component.
  • The exact official route is deep IM. “Slowly” is not stated in the audited primary documents; do not add it or extrapolate IV, SC or oral use.
  • AEM and the Kazakhstan SPC describe a human medicine; this is not a veterinary authorisation. Exact dog/cat PK, efficacy and repeated-dose safety remain absent.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each 3 ml ampoule contains 250 mg pyridoxine and 60 mg benzyl alcohol with the other vitamins. Dog/cat local tolerance, repeated-dose safety and therapeutic margin are not established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Parenteral thiamine can cause serious hypersensitivity. Use aseptic technique, review excipients and ensure readiness to manage an acute reaction.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron B Azerbaijan register2022
  2. Benevron B Kazakhstan SPC2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Thiamine83.33 mg/ml Pyridoxine83.33 mg/ml Cyanocobalamin0.5 mg/ml Riboflavin1.333 mg/ml
Formulation Type
Solution
Administration route
Intramuscular
Registration
Georgia Yes, human
In force until 02 Jun 2031
Human (Ministry of Health, RAMA)
№ რ-045603, რ-038060
Verified on: 15 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog or cat dose was identified for this exact high-dose four-vitamin ampoule. The official human information specifies deep intramuscular administration; it does not say slowly and its human schedule cannot establish a veterinary ml/kg regimen.

Benevron BF 20 gastro-resistant tablets, Coated tablet

human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron BF

20 gastro-resistant tablets, human medicine
Assessed clinical scopeDog · Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role · By mouth
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-046262, რ-044386 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical canine score cannot be assigned responsibly. AEM DV 25-00460 verifies the Azerbaijani gastro-resistant medicine, while the exact World Medicine Kazakhstan document describes the same name, composition and 20-tablet presentation as a food supplement. Neither source establishes a dog/cat regimen, veterinary PK, target-animal safety or outcomes; neither establishes a validated veterinary fraction.

Exact identity is documented, but the regulatory category differs by jurisdiction and no veterinary dose or validated tablet fraction is established.

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact product. Do not restore a quarter-tablet practice or derive a fraction by arithmetic.
  • The exact presentation is gastro-resistant, but the audited primary documents do not establish scoring, equal-dose subdivision, whole-only administration or crushing instructions. Do not invent any of them.
  • AEM records a human medicine in Azerbaijan; the exact World Medicine Kazakhstan document calls the same name/composition/presentation a food supplement. Keep the jurisdiction-specific categories distinct.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each tablet contains 200 mg pyridoxine with four other vitamins. No product-specific dog/cat exposure threshold, safe duration or therapeutic margin is established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Review hypersensitivity to active ingredients and excipients. The exact product document lists sulfite and paraben excipients; target-animal tolerability is not established.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron BF Azerbaijan register2025
  2. Benevron BF manufacturer document2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron BF

20 gastro-resistant tablets, human medicine
Assessed clinical scopeCat · Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role · By mouth
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-046262, რ-044386 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical feline score cannot be assigned responsibly. AEM DV 25-00460 verifies the Azerbaijani gastro-resistant medicine, while the exact World Medicine Kazakhstan document describes the same name, composition and 20-tablet presentation as a food supplement. Neither source establishes a dog/cat regimen, veterinary PK, target-animal safety or outcomes; neither establishes a validated veterinary fraction.

Exact identity is documented, but the regulatory category differs by jurisdiction and no veterinary dose or validated tablet fraction is established.

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact product. Do not restore a quarter-tablet practice or derive a fraction by arithmetic.
  • The exact presentation is gastro-resistant, but the audited primary documents do not establish scoring, equal-dose subdivision, whole-only administration or crushing instructions. Do not invent any of them.
  • AEM records a human medicine in Azerbaijan; the exact World Medicine Kazakhstan document calls the same name/composition/presentation a food supplement. Keep the jurisdiction-specific categories distinct.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each tablet contains 200 mg pyridoxine with four other vitamins. No product-specific dog/cat exposure threshold, safe duration or therapeutic margin is established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Review hypersensitivity to active ingredients and excipients. The exact product document lists sulfite and paraben excipients; target-animal tolerability is not established.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron BF Azerbaijan register2025
  2. Benevron BF manufacturer document2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Thiamine250 mg Pyridoxine200 mg Riboflavin15 mg Folic acid0.5 mg Cyanocobalamin0.25 mg
Formulation Type
Coated tablet
Administration route
By mouth
Registration
Georgia Yes, human
In force until 08 Sep 2031
Human (Ministry of Health, RAMA)
№ რ-046262, რ-044386
Verified on: 15 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog or cat dose was identified for this exact high-dose five-vitamin gastro-resistant product. The exact public documents contain human directions only and do not establish tablet subdivision, crushing, veterinary exposure or a treatment course.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗